Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $45.00 | Buy | Craig Hallum |
| 12/5/2024 | $38.00 → $37.00 | Buy → Neutral | Goldman |
| 11/15/2024 | $50.00 | Outperform | Wolfe Research |
| 10/16/2024 | $43.00 | Buy | UBS |
| 10/10/2024 | $40.00 | Buy | Guggenheim |
| 2/23/2024 | $30.00 → $33.00 | Buy | Needham |
| 1/18/2023 | Outperform → Mkt Perform | Raymond James | |
| 1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
10-Q - VERACYTE, INC. (0001384101) (Filer)
8-K - VERACYTE, INC. (0001384101) (Filer)
SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
SC 13G - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter of 2025 after the close of market on Wednesday, May 7, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/5r4msrbq. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/
Grew fourth quarter total revenue to $118.6 million, an increase of 21% Grew fourth quarter testing revenue to $112.2 million, an increase of 24% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. "I'm incredibly proud of what our team accomplished in 2024," said Marc Stapley, Veracyte's chief executive officer. "We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant opportunities for Decipher and Afirma to impact
Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a
Veracyte, Inc. (NASDAQ:VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has spread beyond the primary tumor. The Decipher Prostate test, already widely used for patients with localized disease, is now the only gene expression test available and covered by Medicare to inform treatment decisions for patients across the full continuum of prostate cancer risk. Veracyte has begun making the Decipher Prostate Metastatic test available to select clinical sites through an early access program and will begin taking orders for the test more broadly in June 2025. Prostate cancer i
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2025, the annual meeting of the American Urological Association, taking place April 26-29 in Las Vegas. Study findings to be presented include new data from the use of the Decipher tests in clinical trials as well as insights into these cancers' underlying biology, which researchers derived through use of the whole-transcriptome-based Decipher GRID (Genomic Resource for Intelligent Discovery) research tool. "Our whole-transcriptome approach to Decipher testing provides us with a rich
Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00
Goldman downgraded Veracyte from Buy to Neutral and set a new price target of $37.00 from $38.00 previously
Wolfe Research initiated coverage of Veracyte with a rating of Outperform and set a new price target of $50.00
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac
Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a
Veracyte, Inc. (NASDAQ:VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately. "We are thrilled to welcome Eliav Barr to our board," said Marc Stapley, Veracyte's chief executive officer. "Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology." Dr. Barr has built his distinguished career at Merck Research Labo